TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21224820
Drug: Heparin-coated ECC-set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated ECC-set (group C)
Study: 16995587
Drug: Low-dose ACTH
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ACTH test (LDT)
Study: 16995587
Drug: Standard-dose ACTH
Normalized name: ACTH
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard-dose ACTH test (SDT)
Study: 16995587
Drug: Budesonide (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (400 μg or 600 μg daily doses)
Study: 16995587
Drug: 24-hour urinary
Normalized name: Urinary hCG
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-hour urinary free cortisol excretion
Study: 9292541
Drug: RheothRx (poloxamer
Approvals — FDA: no, EMA: no, PMDA: no
Description: RheothRx (poloxamer 188) Injection
Study: 8038025
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of atropine (target heart rate 100 beats/min)
Study: 8038025
Drug: Additional infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Additional infusion of adrenaline and noradrenaline
Study: 3524645
Drug: Magnesium supplementation
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium supplementation (both intravenous and oral)
Study: 28279428
Drug: Nadroparin (2850
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadroparin (2850 IE anti‐Xa=0.3ml daily subcutaneous self-injection)
Study: 28279428
Drug: Fondaparinux (2.5mg=0.5ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fondaparinux (2.5mg=0.5ml daily subcutaneous self-injection)
Study: 23469888
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg single oral dose of memantine
Study: 27653085
Drug: MedGem (MG)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MedGem (MG)
Study: 17062805
Drug: MedGem (MG)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MedGem (MG) sitting position
Study: 17062805
Drug: MedGem (MG)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MedGem (MG) supine position
Study: 10935781
Drug: Insulin(GIK)
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin(GIK)
Study: 8967706
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate (1000 mg/d) and vitamin D3 (500 IU/d)
Study: 1390144
Drug: Roxithromycin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxithromycin (150 mg b.i.d. orally)
Study: 1390144
Drug: Penicillin (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penicillin (2.5 MU x 8 daily intravenously, then 6 MU daily orally)
Study: 2983909
Drug: High-dose naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose naloxone (5.4 mg/h)
Study: 2983909
Drug: Low-dose naloxone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose naloxone (0.8 mg/h)
Study: 23302973
Drug: Subcutaneous etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous etanercept 50 mg administered 90 minutes before surgery
Study: 18164672
Drug: rhGH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGH treatment (4.5 IU intramuscularly daily for 4 weeks)
Study: 16505196
Drug: Carotid augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carotid augmentation index
Study: 15243933
Drug: CVD 909
Normalized name: Vibrio cholerae CVD 103-HGR strain live antigen Oral Suspension [Vaxchora]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVD 909 (oral attenuated typhoid vaccine) at doses of 10(6-9) cfu
Study: 10211027
Drug: Nafamostat 0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nafamostat 0.02 mg kg‐1
Study: 10211027
Drug: Control (5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (5% glucose 0.02 ml kg‐1)
Study: 7943305
Drug: Daily rhGH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily rhGH (0.15 mg somatotropin · kg‐1 · day‐1) intramuscular injections
Study: 7943305
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition with daily rhGH
Study: 31419155
Drug: Verb Network
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verb Network Strengthening Treatment (VNeST), 15 hours of therapy delivered by experienced speech-language pathologists.
Study: 31419155
Drug: Intensive therapy
Normalized name: Cortaid Intensive Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive therapy (as part of the study condition).
Study: 31419155
Drug: Distributed therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distributed therapy (as part of the study condition).
Study: 24595305
Drug: Ingestion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ingestion of 15 g of whey protein after REX in ED
Study: 24595305
Drug: Ingestion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ingestion of 30 g of whey protein after REX in ED
Study: 20146794
Drug: Transmural nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transmural nutritional support (energy and protein enriched diet, two additional servings of an oral nutritional supplement, vitamin D and calcium supplementation, consultations by a dietitian)
Study: 12788879
Drug: GLP-1 infusion
Normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 infusion at 0.4 pmol/kg x min
Study: 12788879
Drug: GLP-1 infusion
Normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 infusion at 0.8 pmol/kg x min
Study: 12788879
Drug: GLP-1 infusion
Normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 infusion at 1.2 pmol/kg x min
Study: 12788879
Drug: GLP-1 infusion
Normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 infusion (all doses)
Study: 1351796
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of loratadine
Study: 26804606
Drug: Cognitive stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive stimulation program administered by volunteers for eight weeks, three times each week
Study: 24890747
Drug: 12-hour magnesium
Normalized name: magnesium chloride 12 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-hour magnesium sulfate therapy
Study: 24890747
Drug: 24-hour magnesium
Normalized name: 24 Hour Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-hour magnesium sulfate therapy
Study: 15919798
Drug: hOKT3gamma1(Ala-Ala) monoclonal
Normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: hOKT3gamma1(Ala-Ala) monoclonal antibody
Study: 12843392
Drug: N-methyl-D-aspartate-receptor blocker
Normalized name: N-methyl-D-glucamine
DrugBank: Meglumine (DB09415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-methyl-D-aspartate-receptor blocker
Study: 12843392
Drug: Left index
Approvals — FDA: no, EMA: no, PMDA: no
Description: Left index finger (no drug)
Study: 10655977
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg Cu-glycine chelate (CuGC)
Study: 10655977
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg Cu-glycine chelate (CuGC)
Study: 31443886
Drug: Baltimore City
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baltimore City Drug Treatment Court (BCDTC)
Study: 30153453
Drug: Increasing-distance interval
Normalized name: Cistanche tinctoria stem extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing-distance interval training (100–200–300–400–500 m), twice a week for six weeks
Study: 30153453
Drug: Decreasing-distance interval
Normalized name: Cistanche tinctoria stem extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decreasing-distance interval training (500–400–300–200–100 m), twice a week for six weeks
Study: 28229646
Drug: PT +
Normalized name: PT-2385
DrugBank: PT-2385 (DB16055)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PT + NT (Physical Training + Nutritional Therapy)
Study: 24680961
Drug: Immediate release
Normalized name: Namenda, immediate release oral kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate release tablet Sirdalud(®)
Study: 22985205
Drug: Fluoxetine-only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine-only
Study: 20030470
Drug: Acetaminophen 1000
Normalized name: acetaminophen 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 1000 mg with tapentadol IR 80 mg
Study: 20030470
Drug: Naproxen 500
Normalized name: naproxen 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 500 mg with tapentadol IR 80 mg
Study: 20030470
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid 325 mg with tapentadol IR 80 mg
Study: 20030470
Drug: Tapentadol IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapentadol IR 80 mg alone
Study: 15949725
Drug: BQ-123 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: BQ-123 (10 nmol/min) + L-NMMA (2 micromol/min)
Study: 15949725
Drug: BQ-123 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: BQ-123 (50 nmol/min) + L-NMMA (4 micromol/min)
Study: 9728850
Drug: Desflurane at
Normalized name: Desflurane
DrugBank: Desflurane (DB01189)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desflurane at 1 L/min
Study: 9728850
Drug: Isoflurane at
Normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoflurane at 1 L/min
Study: 9728850
Drug: Esmolol infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol infusion with desflurane
Study: 9728850
Drug: Esmolol infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol infusion with isoflurane
Study: 2914739
Drug: Preventive antiarrhythmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive antiarrhythmic treatment
Study: 1112170
Drug: Thiordazine (THI)
Normalized name: Thioridazine
DrugBank: Thioridazine (DB00679)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thiordazine (THI) at single daily doses not exceeding 375 mg/day for 6 months
Study: 1112170
Drug: Pimozide (PIM)
Normalized name: Pimozide
DrugBank: Pimozide (DB01100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pimozide (PIM) at single oral doses not exceeding 16 mg/day
Study: 1112170
Drug: Both drug
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both drug groups (THI and PIM)
Study: 31492912
Drug: PCA (proton
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCA (proton pump inhibitors, clarithromycin, and amoxicillin)
Study: 20965780
Drug: Pramipexole (0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramipexole (0.125 to 0.75 mg once daily)
Study: 16804427
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated influenza vaccine (LAIV; FluMist)
Study: 11101476
Drug: High-meat diet
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-meat diet (600 g/d)
Study: 8833212
Drug: Cyclical clodronate
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclical clodronate therapy (200 mg IV infusion every 3 weeks)
Study: 1317089
Drug: Modified soft
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified soft jelly capsule containing nonoxynol-9 (DF-486)
Study: 2859931
Drug: Diltiazem 90
Normalized name: diltiazem 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 90 mg qid (mean dose 340 mg/day)
Study: 24825416
Drug: LY1 dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY1 dosing algorithm
Study: 24825416
Drug: LY2 dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2 dosing algorithm
Study: 24825416
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (GL) dosing algorithm
Study: 22301439
Drug: CD4(+) T-cell-guided
Normalized name: Autologous CD4+CD25hiFoxP3+regulatory T cells
DrugBank: Autologous CD4+CD25hiFoxP3+regulatory T cells (DB18655)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD4(+) T-cell-guided therapy interruption (TI)
Study: 22301439
Drug: therapy continuation
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: therapy continuation
Study: 11994612
Drug: Telephone interviews
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone interviews with health care providers regarding breast implant concerns
Study: 10201101
Drug: Differential observing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Differential observing response procedure; no specific dosage or duration mentioned.
Study: 10201101
Drug: Baseline condition;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline condition; no specific dosage or duration mentioned.
Study: 218717
Drug: Thymosin 60
Normalized name: chymosin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymosin 60 mg/m2 (T60)
Study: 218717
Drug: Thymosin 20
Normalized name: chymosin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymosin 20 mg/m2 (T20)
Study: 27650432
Drug: Cognitive-behaviour therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behaviour therapy (CBT) including psychoeducation, breathing training, and cognitive restructuring over a 6-month period
Study: 24415784
Drug: Rosuvastatin 10
Normalized name: rosuvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 10 mg daily for 24 weeks
Study: 23094055
Drug: VS411 (didanosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: VS411 (didanosine 200 mg/HC 900 mg once-daily)
Study: 17255270
Drug: Dose-dense chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-dense chemotherapy (DDCT)
Study: 12431240
Drug: Standard CHOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard CHOP (-like) chemotherapy
Study: 12431240
Drug: Standard local
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard local practice (SLP) chemotherapy
Study: 12431240
Drug: Elderly patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elderly patients receiving SLP chemotherapy
Study: 3312824
Drug: Phosphocreatine (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphocreatine (8 to 10 mmol/L) in a blood cardioplegic solution
Study: 27085828
Drug: Neoadjuvant TKI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant TKI therapy prior to CN (Group 2)
Study: 27085828
Drug: Neoadjuvant TKI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant TKI therapy (Group 2)
Study: 22672586
Drug: Sitagliptin 100
Normalized name: SITagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 100 mg q.d. added to ongoing open-label metformin (1000 or 1700 mg/day) for 24 weeks
Study: 22672586
Drug: Placebo added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo added to ongoing open-label metformin (1000 or 1700 mg/day) for 24 weeks
Study: 20493644
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual plus assessment (TAU+)
Study: 15341662
Drug: Crocus sativus
Normalized name: CROCUS SATIVUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crocus sativus (saffron) 30 mg/day (TDS)
Study: 15341662
Drug: Imipramine 100
Normalized name: trimipramine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine 100 mg/day (TDS)
Study: 10733632
Drug: Oral-PUVA
Normalized name: Oral Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral-PUVA
Study: 25260393
Drug: Fu Zheng
Normalized name: fu ling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fu Zheng decoction combined with antibiotics
Study: 25260393
Drug: Antibiotic only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic only treatment
Study: 19360898
Drug: LY450139 (gamma-secretase
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY450139 (gamma-secretase inhibitor) 100mg
Study: 19360898
Drug: LY450139 (gamma-secretase
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY450139 (gamma-secretase inhibitor) 140mg
Study: 19360898
Drug: LY450139 (gamma-secretase
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY450139 (gamma-secretase inhibitor) 280mg
Study: 14758296
Drug: Electrical twitch-obtaining
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrical twitch-obtaining intramuscular stimulation (ETOIMS)
Study: 11527248
Drug: Cromolyn sodium
Normalized name: Cromolyn Sodium
DrugBank: Cromoglicic acid (DB01003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cromolyn sodium (20 mg/2 mL, or 1 ampoule; Fujisawa, Osaka, Japan) four times daily for 1 week
Study: 11527248
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 mL of saline) four times daily for 1 week
Study: 8420685
Drug: Carboplatin 300
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin 300 mg/m2 plus Cyclophosphamide 600 mg/m2
Study: 8420685
Drug: Cisplatin 100
Normalized name: CISPLATIN 100MG/VIL (PF) INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 100 mg/m2 plus Cyclophosphamide 600 mg/m2
Study: 26718415
Drug: Leucine supplementation
Normalized name: Leucine
DrugBank: Leucine (DB00149)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leucine supplementation (0.06 g ∙ kg(‐1) ∙ meal(‐1))
Study: 15728889
Drug: Tefibazumab 2
Normalized name: Tefibazumab
DrugBank: Tefibazumab (DB16378)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tefibazumab 2 mg/kg
Study: 15728889
Drug: Tefibazumab 5
Normalized name: Tefibazumab
DrugBank: Tefibazumab (DB16378)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tefibazumab 5 mg/kg
Study: 15728889
Drug: Tefibazumab 10
Normalized name: Tefibazumab
DrugBank: Tefibazumab (DB16378)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tefibazumab 10 mg/kg
Study: 15728889
Drug: Tefibazumab 20
Normalized name: Tefibazumab
DrugBank: Tefibazumab (DB16378)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tefibazumab 20 mg/kg
Study: 12853233
Drug: Arotinolol 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arotinolol 10 mg per day
Study: 12853233
Drug: Arotinolol 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arotinolol 20 mg per day
Study: 12853233
Drug: Arotinolol 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arotinolol 30 mg per day
Study: 12853233
Drug: Propranolol 40
Normalized name: propranolol 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 40 mg per day
Study: 12853233
Drug: Propranolol 80
Normalized name: propranolol 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 80 mg per day
Study: 12853233
Drug: Propranolol 160
Normalized name: propranolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 160 mg per day
Study: 10491227
Drug: Oral 1,25(OH)2D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 1,25(OH)2D3 (1.5 microg/m2 BSA)
Study: 10491227
Drug: Intravenous 1,25(OH)2D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 1,25(OH)2D3 (1.5 microg/m2 BSA)
Study: 10491227
Drug: Sr absorption
Normalized name: ABSORPTION BASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sr absorption without 1,25(OH)2D3 (test A)
Study: 10491227
Drug: Concurrent administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent administration of Sr and oral 1,25(OH)2D3 (test B)
Study: 10491227
Drug: Concurrent administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent administration of Sr and iv 1,25(OH)2D3 (test C)
Study: 8699600
Drug: Unilateral thyroarytenoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unilateral thyroarytenoid muscle injections of 15 units of botulinum toxin
Study: 8699600
Drug: Bilateral thyroarytenoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral thyroarytenoid muscle injections of 2.5 units of botulinum toxin on each side
Study: 1664833
Drug: Oral temafloxacin
Normalized name: TEMAFLOXACIN
DrugBank: Temafloxacin (DB01405)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral temafloxacin 600 mg twice daily (n = 49)
Study: 1664833
Drug: Intravenous cefotaxime
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cefotaxime 2 g thrice daily (n = 51)
Study: 7039882
Drug: Immunosuppressive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunosuppressive treatment (intense immunosuppression followed by long-term maintenance on azathioprine)
Study: 7039882
Drug: Cells taken
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cells taken from patients before treatment
Study: 31693519
Drug: Preventative multimodal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventative multimodal analgesia (PMA) including 1000 mg of acetaminophen, 300-900 mg of gabapentin, and 200-400 mg of celecoxib 1 hour before surgery
Study: 31693519
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg of morphine-equivalent dose (MED) preoperatively
Study: 29946148
Drug: Metformin add-on
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin add-on to continuous subcutaneous insulin infusion (Met + CSII)
Study: 26787402
Drug: Apple intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apple intake (increase of 53 g/d)
Study: 26787402
Drug: Apple intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apple intake of 5-100 g/d
Study: 26787402
Drug: Apple intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apple intake of >100 g/d (an apple a day)
Study: 26787402
Drug: Apple intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apple intake <5 g/d (control group)
Study: 24610902
Drug: Conservative management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative management without intervention and antithrombotic therapy (control group).
Study: 22583697
Drug: Alogliptin 12.5
Normalized name: alogliptin 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alogliptin 12.5 mg + metformin
Study: 22583697
Drug: Alogliptin 25
Normalized name: alogliptin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alogliptin 25 mg + metformin
Study: 22583697
Drug: Alogliptin (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alogliptin (12.5 or 25 mg) + metformin
Study: 17270058
Drug: OROS hydromorphone
Approvals — FDA: no, EMA: no, PMDA: no
Description: OROS hydromorphone 8 mg
Study: 17270058
Drug: OROS hydromorphone
Approvals — FDA: no, EMA: no, PMDA: no
Description: OROS hydromorphone 16 mg